Upfront Pembrolizumab Doubles PFS in MSI-H/dMMR Metastatic CRC Upfront Pembrolizumab Doubles PFS in MSI-H/dMMR Metastatic CRC

Pembrolizumab outperformed chemotherapy in patients with microsatellite-instability high/mismatch repair-deficient metastatic colorectal cancer in the KEYNOTE-177 study.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news